Global Dengue Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Dengue Market was valued at $1.4 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 12.5% CAGR, to an estimated market size of $2.6 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global dengue market encompasses the vaccines, diagnostic testing, and therapeutic interventions (primarily supportive care and fluid management) used to prevent, detect, and manage infections caused by the dengue virus. The scope includes live attenuated vaccines, nucleic acid-based vaccines, rapid diagnostic kits, ELISA-based tests, and molecular diagnostics (RT-PCR), while excluding general mosquito control chemicals and non-specific antipyretics.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Dengue Market in the period 2025-30:
- The market is undergoing a structural shift from supportive care to vaccine-driven prevention following the rollout of second-generation vaccines like Qdenga.
- Climate change and rapid urbanization are expanding the geographical range of Aedes mosquitoes into previously temperate zones, increasing the global at-risk population.
- There is an increasing adoption of Point-of-Care (POC) and multiplex testing that allows for the simultaneous detection of dengue, Zika, and Chikungunya.
- Government-led immunization programs and support from global health organizations like GAVI are improving vaccine accessibility in high-burden endemic regions.
- The integration of Artificial Intelligence (AI) in vaccine development is significantly accelerating clinical trial timelines and improving antigen delivery accuracy.
- Rising demand for travel medicine in non-endemic regions like the US and Europe is creating a high-value market segment for preventative vaccinations.
- Expansion of cold chain infrastructure in emerging economies is facilitating the distribution of temperature-sensitive parenteral vaccines to rural areas.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- Asia-Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Segments
- Vaccines
- Diagnostics & Testing
- Therapeutics & Supportive Care